---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-092871"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2023-08-17T23:59:59+00:00"
generated_at: "2026-06-11T08:01:27.333088+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in cholangiocarcinoma

## Summary
- FDA granted Orphan Drug Designation to NXP800 for cholangiocarcinoma.
- NXP800 is an oral small molecule targeting ARID1a-mutated cancers.
- Phase 1b trial ongoing in ARID1a-mutated ovarian carcinoma; cholangiocarcinoma expansion planned.
- CEO Ron Bentsur cites unmet medical need in cholangiocarcinoma.

## SEC filing metadata
- accession: 0001104659-23-092871
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2023-08-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465923092871/0001104659-23-092871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465923092871/tm2323981d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-092871
- JSON: https://secwatch.observer/filing/0001104659-23-092871.json
- Plain text: https://secwatch.observer/filing/0001104659-23-092871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.